Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Rahul Ray

Showing results (31-40 of 37) with videos related to

Pageof 4
Sort By:
You have reached the last page of results.This site can display upto 37 results.
The Journal of Investigative Dermatology|January 15, 2013
1α,25-Dihydroxyvitamin-D3-3-bromoacetate regulates AKT/mTOR signaling cascades: a therapeutic agent for psoriasisAnanya Datta Mitra, Siba P Raychaudhuri, Christine J Abria, et al.
Anticancer Research|March 9, 2012
Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine modelRahul Ray, Mara Banks, Hilal Abuzahra, et al.
Neoplasia (New York, N.Y.)|March 28, 2003
Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in miceOliver Kisker, Shinya Onizuka, Christian M Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cellsNarasimha Swamy, Tai C Chen, Sara Peleg, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 15, 2010
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growthJames R Lambert, Vikram J Eddy, Christian D Young, et al.
Oncotarget|February 25, 2016
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancersHamid H Gari, Christy M Gearheart, Susan Fosmire, et al.
Scientific Reports|July 24, 2021
Adenosine deaminase modulates metabolic remodeling and orchestrates joint destruction in rheumatoid arthritisSai Krishna Srimadh Bhagavatham, Prakash Khanchandani, Vishnu Kannan, et al.
Pageof 4

Showing results (31-40 of 37) with videos related to

Sort By:
Pageof 4
You have reached the last page of results.This site can display upto 37 results.
The Journal of Investigative Dermatology|January 15, 2013
1α,25-Dihydroxyvitamin-D3-3-bromoacetate regulates AKT/mTOR signaling cascades: a therapeutic agent for psoriasisAnanya Datta Mitra, Siba P Raychaudhuri, Christine J Abria, et al.
Anticancer Research|March 9, 2012
Effect of dietary vitamin D and calcium on the growth of androgen-insensitive human prostate tumor in a murine modelRahul Ray, Mara Banks, Hilal Abuzahra, et al.
Neoplasia (New York, N.Y.)|March 28, 2003
Vitamin D binding protein-macrophage activating factor (DBP-maf) inhibits angiogenesis and tumor growth in miceOliver Kisker, Shinya Onizuka, Christian M Becker, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 9, 2004
Inhibition of proliferation and induction of apoptosis by 25-hydroxyvitamin D3-3beta-(2)-Bromoacetate, a nontoxic and vitamin D receptor-alkylating analog of 25-hydroxyvitamin D3 in prostate cancer cellsNarasimha Swamy, Tai C Chen, Sara Peleg, et al.
Cancer Prevention Research (Philadelphia, Pa.)|December 15, 2010
A vitamin D receptor-alkylating derivative of 1α,25-dihydroxyvitamin D3 inhibits growth of human kidney cancer cells and suppresses tumor growthJames R Lambert, Vikram J Eddy, Christian D Young, et al.
Oncotarget|February 25, 2016
Genome-wide functional genetic screen with the anticancer agent AMPI-109 identifies PRL-3 as an oncogenic driver in triple-negative breast cancersHamid H Gari, Christy M Gearheart, Susan Fosmire, et al.
Scientific Reports|July 24, 2021
Adenosine deaminase modulates metabolic remodeling and orchestrates joint destruction in rheumatoid arthritisSai Krishna Srimadh Bhagavatham, Prakash Khanchandani, Vishnu Kannan, et al.
Pageof 4